Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8101599 | NOVARTIS | Pharmaceutical composition containing anti-hypertensive agents |
May, 2023
(23 days ago) | |
US8475839 | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
May, 2023
(23 days ago) | |
US8475839 (Pediatric) | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
Nov, 2023
(5 months from now) |
Market Authorisation Date: 30 April, 2009
Treatment: NA
Dosage: TABLET;ORAL
8
United States
4
China
3
Korea, Republic of
3
Japan
3
Peru
3
European Union
2
Canada
2
Brazil
2
Hong Kong
2
Taiwan
2
Argentina
2
Mexico
2
New Zealand
2
Australia
2
Norway
2
South Africa
2
Ecuador
2
Russia
1
Chile
1
Poland
1
Slovenia
1
Egypt
1
Morocco
1
Germany
1
Cyprus
1
Denmark
1
Malaysia
1
Spain
1
Austria
1
Portugal
1
Tunisia
1
Israel
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic